Daniel Rosenbluth

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 496 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

Eitan Kerem, Michael W. Konstan, K. De Boeck et al. · The Lancet Respiratory Medicine · 2014 · 335 citations · Full text

Medicine, Molecular Medicine, Pharmacotherapy +9

Gender Differences in Outcomes of Patients with Cystic Fibrosis

Cayce L. Harness‐Brumley, Alan C. Elliott, Daniel Rosenbluth et al. · Journal of Women s Health · 2014 · 202 citations · Full text

Public Health, Biostatistics, Infectious Diseases +16

Lung Function Decline in Cystic Fibrosis Patients and Timing for Lung Transplantation Referral

Daniel Rosenbluth, Kevin Wilson, Thomas W. Ferkol et al. · CHEST Journal · 2004 · 157 citations

Medicine, Surgery, Pulmonary Function Testing +14

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8